RxDoctor Payments Data

Paula Ravin, MD

Neurology · Los Angeles, CANPI 1558346130

Payments from drug & device makers

$211,614in general payments, 2019–2025

Across 276 payments — averaging $766.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Adamas Pharmaceuticals, Inc.$96K
  • MDD US Operations, LLC$73K
  • Kyowa Kirin, Inc.$34K
  • Acadia Pharmaceuticals Inc$8K
  • Amneal Pharmaceuticals LLC$530
  • AbbVie$271
  • plus $718 from 10 others

What the payments were for

  • Consulting fees$15,1877%
  • Speaking & faculty fees$171,43081%
  • Travel & lodging$20,0569%
  • Food & beverage$4,9332%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$211,614 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$207,665
Medicare patients
215
Services billed
18,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa339$564,564
AustedoDeutetrabenazine32$371,001
NuplazidPimavanserin Tartrate30$235,281
GocovriAmantadine Hcl64$191,511
IngrezzaValbenazine Tosylate16$124,682
NourianzIstradefylline17$48,999
NeuproRotigotine32$25,436
XadagoSafinamide Mesylate12$14,958
Rasagiline Mesylate72$14,739
LinzessLinaclotide23$14,716
Carbidopa-LevodopaCarbidopa/Levodopa324$13,939
MyrbetriqMirabegron25$12,879
Rivastigmine17$3,067
Primidone28$2,156
Ropinirole Hcl70$2,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$530$564,564339 claims
Acadia Pharmaceuticals IncNuplazid$7,902$235,28130 claims
MDD US Operations, LLCGocovri$72,532$191,51164 claims
Neurocrine Biosciences, Inc.Ingrezza$37$124,68216 claims
Kyowa Kirin, Inc.Nourianz$33,611$48,99917 claims
AbbVieLinzess$271$14,71623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →